REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Conference Call Information
When: Monday, November 6, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI0eececfba52f4f83a7438c9f002fabc4
Webcast: https://edge.media-server.com/mmc/p/z2fatkzx
A press release containing the third quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call. Please also review our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which will be available at https://investors.coherus.com and available via EDGAR on the SEC’s website at www.sec.gov on November 6, 2023 for more information about our third quarter financial results.
A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.
Coherus Contact Information:
Jodi Sievers
VP, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.12 |
Daily Change: | 0.11 10.89 |
Daily Volume: | 2,987,927 |
Market Cap: | US$129.040M |
March 10, 2025 January 22, 2025 January 08, 2025 December 18, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load